Research Study

A Phase 3 Study to Evaluate the Safety and Efficacy of 99mTc-MIP-1404 SPECT/CT Imaging to Detect Clinically Significant Prostate Cancer in Men With Biopsy Proven Low-Grade Prostate Cancer Who Are Candidates for Active Surveillance (proSPECT-AS)
Principal Investigator 
Philip Cohen

Overview

Body Locations and Systems 
Prostate Cancer
ClinicalTrials.gov# 
NCT02615067
Status 
Recruiting
Study Start/End 
Jul 4, 2016 to Sep 1, 2017
Locations 
Diamond Health Care Centre, Lions Gate Hospital, Vancouver General Hospital
Name/Title 
Kessie Xu, Research Coordinator
Phone 
604-875-4111 ext.69487
Email Address 
kessie.xu@vch.ca
Purpose of Study 

99mTc-MIP-1404 is a radioactive diagnostic imaging agent indicated for imaging men with newly diagnosed prostate cancer whose biopsy indicates a histopathologic Gleason grade of ≤ 3+4 severity and / or are candidates for active surveillance, but have planned to undergo radical prostatectomy. In these patients, the results may be used to help estimate the risk of a histopathologic Gleason grade of > 3+4. This Phase 3 study is designed to evaluate the specificity and sensitivity of 99mTc-MIP-1404 to detect clinically significant prostate cancer when compared to histopathology.

Eligibility 

Visit ClinicalTrials.gov for more information.

Disclaimer 

Study Coordinators and Research Nurses cannot give medical advice over the phone. Telephone numbers and email addresses are provided for obtaining additional information on specific clinical research trials only. If you have specific questions which require clinical expertise, please call your primary care physician.